Breaking News
Get 40% Off 0
Close

Gilead Sciences Inc (GILD)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
66.50 +0.60    +0.91%
13:36:07 - Closed. Currency in EUR ( Disclaimer )
Type:  Equity
Market:  Germany
ISIN:  US3755581036 
S/N:  885823
  • Volume: 791
  • Bid/Ask: 66.62 / 66.66
  • Day's Range: 65.58 - 66.74
Gilead 66.50 +0.60 +0.91%

Gilead Sciences Inc Company Profile

 
Get an in-depth profile of Gilead Sciences Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

17000

Equity Type

ORD

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Merck & Co, Inc., and Tentarix Biotherapeutics Inc., as well as a partnership with Assembly Biosciences, Inc. to develop next-generation therapeutics for serious viral diseases. The company was incorporated in 1987 and is headquartered in Foster City, California.

Contact Information

Address 333 Lakeside Drive
Foster City, 94404
United States
Phone 650 574 3000
Fax 650 522 5853

Top Executives

Name Age Since Title
Daniel P. O'Day 57 2019 Chairman & CEO
Paul Berg 96 1998 Member of Scientific Advisory Board
Grace E. Colon 56 2023 Chairman of the Board
Francis V. Chisari - - Member of the Scientific Advisory Board
Brian J. Druker 67 - Member of the Scientific Advisory Board
Jacqueline K. Barton 70 1989 Independent Director
Kevin E. Lofton 68 2009 Lead Independent Director
Robert T. Schooley - - Member of the Scientific Advisory Board
Kenneth C. Anderson 72 - Member of the Scientific Advisory Board
Mark C. Genovese - - Member of Scientific Advisory Board
Eugene R. Schiff - - Member of the Scientific Advisory Board
John W. Mellors 85 - Member of the Scientific Advisory Board
Eric J. Topol 69 - Member of Scientific Advisory Board
Robert A. Harrington 62 - Member of the Scientific Advisory Board
Paul E. Klotman - - Member of the Scientific Advisory Board
Harish M. Manwani 70 2018 Independent Director
Javier J. Rodriguez 52 2020 Independent Director
Joel R. Huff - - Chairperson of Scientific Advisory Board
Malcolm MacCoss 75 - Member of Scientific Advisory Board
Kelly A. Kramer 55 2016 Independent Director
Nezam H. Afdhal 66 - Member of Scientific Advisory Board
Jeffrey A. Bluestone 70 2020 Independent Director
Sandra J. Horning 74 2020 Independent Director
Anthony Welters 68 2020 Independent Director
Ted W. Love 65 2024 Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

GILD Comments

Write your thoughts about Gilead Sciences Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Luis Anderson
Luis Anderson Jul 14, 2023 9:50AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
time to buy
Bugman CV
Bugman CV Apr 28, 2022 1:44PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Who cares about dividends when this stock shows weakness year after year, is not a good deal to get 5% per year if you are constantly worried about this stock sinks under 2013 lows
Jorge Almeida Pereira
Jorge Almeida Pereira Apr 28, 2022 1:44PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Are you a coinbase client?
Luis Anderson
Luis Anderson Apr 28, 2022 1:44PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Keith Chan
Keith Chan Mar 08, 2022 10:59AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
it sucks...
Dale Le
Dale Le Feb 17, 2022 9:37PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
invest stock gild.us at basel markets to take home divedends
Manny Drake
Manny Drake Jan 28, 2022 3:06PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Projected earnings beat but I'd bet it doesn't move the needle -
Tedeski Rukker
Tedeski Rukker Jan 07, 2022 6:56PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Another 15 or so shares into this.
Ted Trukker
Ted Trukker Nov 19, 2021 2:15PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I've held this since 2014 or so. COULD have picked NVDA for approx 15 - 20 😒Did I pick the winner eh?
BIG John
BIG John Oct 29, 2021 9:48AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Amazing how GILD managed to disappoint on EVERY earnings report.
Ted Trukker
Ted Trukker Oct 29, 2021 9:48AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Yes, even a beat is disapointing -
Amir Amiral
Amir Amiral Oct 18, 2021 12:37PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
What's happening?!
Arvind Ganotra
Arvind Ganotra Oct 18, 2021 12:10PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Everyone in market is here to make money. Gilead saved my wife's life. I will donate all my money for this one organization who is working to safe our life ...
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email